Death-seq identifies regulators of cell death and senolytic therapies

• Published in: bioRxiv
• Main Authors: Colville, Alex, Jie-Yu, Liu, Thomas, Samantha, Ishak, Heather D, Zhou, Ronghao, Klein, Julian Dd, Morgens, David W, Armon Goshayeshi, Salvi, Jayesh S, Yao, David, Spees, Kaitlyn, Bassik, Michael C, Rando, Thomas A
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 03.04.2022; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: Age; Apoptosis; Cell Biology; Cell culture; Cell death; CRISPR; DIABLO protein; Enhancers; Genetic screening; Molecular modelling; Neurodegeneration; Patent applications; Positive selection; Senescence; Synergism; Therapeutic targets; Thrombocytopenia; senescence; CRISPR; genome-wide; Death-seq; cell death; pulmonary fibrosis; synthetic lethality; senolytics; positive selection; Death screen

Selectively ablating senescent cells ("senolysis") is an evolving therapeutic approach for age-related diseases. Current senolytics are limited to local administration by potency and side effects. While genetic screens could identify senolytics, current screens are underpowered for identif...